FGFR2 and cholangiocarcinoma: Indeed, the promising results of pemigatinib and infigratinib were shown in advanced unresectable cholangiocarcinoma harboring FGFR2 fusions or rearrangements [33,34,35], and erdafitinib in metastatic urothelial carcinoma with FGFR2 and FGFR3 genetic aberrations [36].